loader2
Partner With Us NRI

Vimta Labs Ltd share Price Today

Company details

492.25
509.00
385.25
623.15
6M Return 20.25%
1Y Return 20.02%
Mkt Cap.(Cr) 1,100.57
Volume 18,176
Div Yield 0.40%
OI
-
OI Chg %
-
Volume 18,176

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Healthcare Services company Vimta Labs announced consolidated Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Total Income for Q4FY24 was at Rs 802 million
  • EBITDA for Q4FY24 was Rs 249 million; EBITDA margin was at 31.1%
  • Q4FY24 PAT was at Rs 124 million
  • Basic EPS in Q4FY24 was Rs 5.6

FY24 Financial Highlights:

  • Total Income for FY24 was at Rs 3,223 million
  • EBITDA for FY24 was Rs 908 million; EBITDA margins at 28.2%
  • FY24 PAT was at Rs 410 million
  • Basic EPS was Rs 18.5 in FY24
  • Cash flow From Operations at Rs 609 million for FY24; FY24 Capex at Rs 763 million
  • Cash and Cash equivalents at Rs 258 million as of 31st March 2024
  • Debt to Equity ratio 0.06x

Commenting on results, Harita Vasireddi, Managing Director, Vimta Labs Limited, said: “Q4 maintained good recovery after H1 being harsh on us. Having a strong and resilient business model has helped us strive through some headwinds and get back to the historical figures.

Our services to the Pharmaceutical industry have seen a promising uptick, demonstrating growth in both pre-clinical and analytical services. We have recently expanded our offerings to include clinical trials, which we anticipate will be a major driver of future growth.

The Food segment experienced initial setbacks due to supply chain disruptions caused by various external factors. However, this segment has begun to recover and shows promise for continued improvement. Our new Electronics and Electrical testing division delivered strong results, while our other segments have gone through some corrections in services and their scale.

Looking forward, we are confident in our ability to achieve significant growth. While FY24 presented unforeseen challenges, we are optimistic that FY25 will be a year of robust expansion for the company.”

Result PDF

View Other Company Results

Vimta Labs Ltd shares SWOT Analysis

Strengths (7)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Growth in Net Profit with increasing Profit Margin (QoQ)
  • Company with Low Debt

Weakness (6)

  • Inefficient use of capital to generate profits - RoCE declining in the last 2 years
  • Inefficient use of shareholder funds - ROE declining in the last 2 years
  • Inefficient use of assets to generate profits - ROA declining in the last 2 years

Opportunity (0)

Data not found

Threats (1)

  • Promoter decreasing their shareholding

Resistance and support

R1 506.2
R2 516.0
R3 522.9
Pivot

499.22

S1 489.4
S2 482.5
S3 472.7
EMA SMA
489.9
487.5
481.4
470.1
486.6
490.8
482.9
481.5
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
GRAVITON RESEARCH CAPITAL LLP Bulk Purchase 2021-07-22 338.02 153667 NSE
XTX MARKETS LLP Bulk Purchase 2021-07-22 338.22 125571 NSE
GRAVITON RESEARCH CAPITAL LLP Bulk Sell 2021-07-22 337.66 153667 NSE
Name Category Shares
SIVALINGA PRASAD VASIREDDI PROMOTER 11.72%
VANGAL HARRIMAN PROMOTER 8.02%
VASIREDDI VEERABHADRA PRASAD PROMOTER 6.6%
PRAVEENA VASIREDDI PROMOTER 4.97%
HARITA VASIREDDI PROMOTER 0.76%
SIREESH CHANDRA VUNGAL PROMOTER 0.51%
ANDHRA PRADESH INDUSTRIAL DEVELOPMENT CORPORATION LIMITED PROMOTER 2.66%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Vimta Labs Ltd Stocks COMPARISON

Financials( in Cr) Vimta Labs Ltd Central Depository Services (India) Ltd TBO Tek Ltd Indegene Ltd Godrej Agrovet Ltd
Price 496.40 2,073.30 1,607.25 581.95 606.40
% Change -1.21 -1.96 0.04 -0.61 3.31
Mcap Cr 1,100.57 21,665.99 17,452.81 13,924.26 11,655.68
Revenue TTM Cr 318.19 555.09 1,064.59 2,306.13 9,373.68
Net Profit TTM Cr 48.17 275.96 148.49 266.10 295.36
PE TTM 27.16 52.73 83.53 41.76 31.36
1 Year Return 20.02 104.47 14.29 1.94 34.68
ROCE 23.48 31.39 51.92 29.51 10.56
ROE 18.68 23.93 51.90 29.12 10.47
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 281.79 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 32,550.52 645.34
LAST 3M 105,892.14 -28,833.11
LAST 6M 178,978.26 -15,682.85
LAST 12M 290,242.45 102,068.56

Vimta Labs Ltd Information

Stock PE (TTM)
27.16
Promoter Holding
36.92%
Book Value
144.1974
ROCE
23.48%
ROE
18.68%
Description
  • Vimta Labs Ltd., established in 1984, is India`s most comprehensive contract research and testing organization, providing wide range of services to pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device and many other industries. Broadly, these services include: Drug discovery, development and drug life cycle management support services in the areas of preclinical research (GLP and non-GLP), clinical research, central lab, and cGMP as well as non-GMP analytical services for pharmaceutical and biopharmaceutical companies; Preclinical research and testing services for medical device companies; Contract research and testing for Agro-science companies; Food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exporters, regulators; Clinical diagnostics services to patients, clinicians, hospitals and Environmental regulatory services such as impact assessments and post project monitoring, to industries such as infrastructure, power, cement, oil & gas, mining etc. The Company was awarded ISO 9002 Certification under ISO/IEC Guide-25 as Certified Competent Laboratory and Quality Endorsed Company by Standards Australia Quality Assurance Services Pty. Ltd in 1994. In 1997, the Company entered into a Joint Venture with Russian Centre for Testing and Certification, ROSTEST Moscow with an investment of 24% of the total Paidup Captial. The main essence of this Joint Venture was to diversify the activities in to preshipment inspection services for all Indian exports to Russia. During 2002, the company begun to offer Clinical Diagnostics Services. Clinical Specialty Diagnostics has been an internal requirement to screen the clinical trial subjects. Facilities were created in the year 2000 to speed up the clinical trials. The Company is now expanding its operations by five times of its existing capacities at S P Biotech Park, Genome Valley, Turkapally Village, Shamirpet Mandal, Ranga Reddy Dist. The project is expected to commence from September 2005. During the year 2006-07, the Analytical and Clinical Reference Lab facilities was shifted from the existing Cherlapally Facility to the newly established Life Sciences Facility in S.P.Biotech Park, Genome Valley, Hyderabad which started commercial operations from September, 2006. During the year 2020 Company acquired 100% Equity Shares of Emtac Laboratories Private Limited, on 04th March 2020, making Emtac a wholly owned subsidiary of the Company.

Registered Address

Plot No 141/2 & 142, IDA Phase II Cherlapally, Hyderabad, Telangana, 500051

Tel : 91-40-27264141
Email : shares:vimta.com
Website : http://www.vimta.com
Registrar

CIL Securities Limited

AGM Date (Month) : Jun
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 524394
NSE Code : VIMTALABS
Book Closure Date (Month) : Jun
BSE Group : B
ISIN : INE579C01029

FAQ’s on Vimta Labs Ltd Shares

You can buy Vimta Labs Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Vimta Labs Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 18, 2024 03:59 PM the closing price of Vimta Labs Ltd was Rs.496.40.

The latest PE ratio of Vimta Labs Ltd as of Jun 18, 2024 03:59 PM is 27.16

The latest PB ratio of Vimta Labs Ltd as of Jun 18, 2024 03:59 PM is 0.29

The 52-week high of Vimta Labs Ltd share price is Rs. 623.15 while the 52-week low is Rs. 385.25

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 18, 2024 03:59 PM, the market cap of Vimta Labs Ltd stood at Rs. 1,100.57.

Download App

Download Our App

Play Store App Store
market app